• Vaccine Name: ChAd63-MVA RH5
• Target Pathogen: Plasmodium spp.
• Target Disease: Malaria
• Type: Recombinant vector vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: RH5: reticulocyte–binding protein homolog 5: forms a critical nonredundant interaction with its receptor basigin (CD147) on the RBC surface. (Payne et al., 2017)
• RH5 gene engineering:
  • Type: Recombinant protein preparation
  • Description: reticulocyte–binding protein homolog 5 full length sequence (Payne et al., 2017)
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

Human Response

• Host Strain: healthy adults in United Kingdom (Payne et al., 2017)
• Host age: 19–48 years (Payne et al., 2017)
• Host gender: 13 females, 11 males (Payne et al., 2017)
• Vaccination Protocol: Phase I, non-randomized, dose-escalation study.
  Participants were assigned to one of the four groups: 1) 4 volunteers received 1 dose of ChAd63 RH5 5 x 10^9 vp, 2) 4 volunteers received 1 dose of ChAd63 RH5 5 x 10^10 vp, 3) 8 volunteers received 1 dose of ChAd63 RH5 at 5 x 10^10 vp and 1 dose MVA RH5 at 1 x 10^8 pfu 8 weeks later, 4) 8volunteers received 1 dose of ChAd63 RH5 at 5 x 10^10 vp and 1 dose MVA RH5 at 2 x 10^8 pfu 8 weeks later (Payne et al., 2017)
• Immune Response: Cellular: peak of the response on day 14 after primary vaccination, no significant difference between lower-dose priming and higher-dose priming group. Responses contracted by day 56. The booster dose boosted the responses in all volunteers as measured on day 63, no significant difference between lower-dose booster and higher-dose booster group.
  Humoral: induced IgG1 and IgG3 serum antibody response and memory B cells (mBCs). 2 of 4 volunteers in lower-dose priming group and 16 of 20 volunteers in higher-dose priming group showed a detectable response on day 28. Response maintained prior to administration of booster and was boosted as measured on day 84. There was significant difference between high-dose booster group and no booster group. Response in higher-dose booster group tended to be higher than that in lower-dose booster group, but did not reach significance. Response decreased by day 140. (Payne et al., 2017)
• Side Effects: Systematic: nausea, fever, arthralgia, feverish, malaise, myalgia, fatigue, headache; Local: itch, redness, warmth, swelling, pain. Most mild or moderate in severity, all resolved in 24 hours. (Payne et al., 2017)